Cardiovascular Drug Development
Models of cardiac cell have been used to characterize drugreceptor action profiles that avoid arrhythmia to help to identify safer drugs. Such models have also been incorporated into tissue and organ models that enable modeling of arrhythmia (Noble, 2008; PMID: 18566519). Based on this approach, models have been successfully used to predict the side effects of the FDA approved drug Ranolazine for treatment of chronic angina.
The above-mentioned studies clearly indicate that mathematical models have successfully been used to better understand disease dynamics as well as aid in a personalized therapy based on quantitative data derived from patient/pathogen interactions.